,

Metformin use reduces risk of death for patients with COVID-19 and diabetes

Metformin use reduces risk of death for patients with COVID-19 and diabetes - مصرف متفورمین خطر مرگ را در بیماران دیابتی مبتلا به کووید19 کاهش می دهد

Use of the diabetes drug metformin — before a diagnosis of COVID-19 — is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse study at the University of Alabama at Birmingham. Diabetes is a significant comorbidity for COVID-19.

“This beneficial effect remained, even after correcting for age, sex, race, obesity, and hypertension or chronic kidney disease and heart failure,” said Anath Shalev, M.D., director of UAB’s Comprehensive Diabetes Center and leader of the study.

The study — first made available in MedRxiv and now published in the peer-reviewed journal Frontiers in Endocrinology — included 25,326 patients tested for COVID-19 at the tertiary care UAB Hospital between Feb. 25 and June 22 of last year. Of the 604 patients found to be COVID-19-positive, 311 were African Americans.

Release date: 14 January 2021
Source: University of Alabama at Birmingham